Osimertinib mesylate is a mutant epidermal growth factor receptor (EGFR) inhibitor that can penetrate the blood-brain barrier and inhibit tumor cell survival and proliferation in patients with non–small cell lung cancer (NSCLC) with specific EGFR alterations. Here, EGFR is linked to lung cancer.